Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIOP Ependymoma II
NL-OMON59511Phase 3Recruiting
- Sponsor
- Centre Léon Bérard
- Start
- Jul 2020
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of vincristine, etoposide, cyclophosphamide, cisplatin, methotrexate and 1 more in ependymoma (7 arms), sponsored by Centre Léon Bérard. Primary endpoints: Gross total resection rate, Progression-free survival and 1 more. Started Jul 2020; status: recruiting.
02
Drugs
vincristineetoposidecyclophosphamidecisplatinmethotrexate
03
Conditions
ependymoma
Beyond the preview
Go deeper on NL-OMON59511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59511.